|Day Low/High||81.56 / 83.50|
|52 Wk Low/High||65.25 / 92.06|
The firm is obviously fast becoming a real player in creating treatment for certain cancers. The firm still loses money.
That's the really good news about why we could bounce back so quickly from Thursday's debacle.
The administration will provide increased financial support to 5 pharmas working on Covid vaccines, and we must keep an eye on price action in this uncertain market.
The Fed and Treasury are set on avoiding the mistakes that doomed us in the past, and we have to invest for this new market we're in now.
When I first started buying ARCT shares I didn't conceive of a valuation of $1 billion, but I also didn't conceive of the global impact of a pandemic.
WDAY looks ready to break out as traders weigh wether markets are now overbought after this 2-day run.
Rising U.S.-China tensions continue to weigh, but new home sales and stalled continuing jobless claims may be positive catalysts.
So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.
The negatives are being shaken off like a first time rider on a long-time bull which means long remains the name of the game.
I've been long Merck for a long time, since way before this pandemic became part of our lives.
The drugmaker's technical signals have been lackluster of late, but news of these initiatives are giving its shares a lift.
The bullish reversal pattern is appearing not just in single names, but also in whole sectors.
The small biotech's market cap sits at $125 million, the low end of what I believe is fair.
It's imperative that people get back to work, so we have this great compromise -- let's see how it might play out.
Money movers are not buying protection for individual names, but they are starting to bet against the market en masse, while the Russell 2000 ran up 4% on Monday.
In the 2nd of a 3-part series, Jim Cramer goes through all 30 Dow stocks to evaluate what is safe to buy and what you should sell or avoid (like the plague).
Here are a number of things that I'm watching now.
The answer to that question depends on several factors, so let's break them down.
The timing of this morning's rally? Almost simultaneously news broke from both China and the UK of possible drugs to fight coronavirus.
These companies all could be strong -- even if the 2019 nCoV fear spreads.
This is a market that thrives on growth. Tesla has it in spades.
This company made headlines in 2019, and I'm betting on it as a great play -- in many senses of the word -- for this new year.
The company has a collaboration with Merck, and there are far worse partners you could have when working in the cancer segment of biotech.
I have long been enamored with Lisa Su as a Chief Executive.
TG Therapeutics and Exelixis could find themselves on the shopping lists of other companies.
Does it tick the President off that it appears the Chinese would rather not give up in writing any unfair advantages in global trade that they have enjoyed for decades this close to a national election in the U.S.? Of course.
I do expect there to be some early to mid-December profit taking. But to get from here to year end without hitting some mid-month turbulence would be a pleasant surprise.
There are plenty of stocks that have been thrown away for several weeks because of a belief that the Fed and a trade deal will avoid a recession.
Here's how to get in on the trade if it can hold on a pullback to the Oct. 22; also if Facebook's price holds above $186, expect it to go higher.